Latest news for Moberg Pharma (OTC:MBGPF) Stock

Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.

Moberg Pharma AB

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>LUNR</li>
<li>AMD</li>
<li>ACHR</li>
<li>QQQ</li>
<li>$BTC</li>
<li>MSTR</li>
<li>PLTR</li>
<li>GOOGL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

$BTC

ACHR

GOOGL

LUNR

MSTR

NVDA

PLTR

TSLA

Top 10 Trending Stocks On WallStreetBets As Of December 26, 2024 (Via Swaggy Stocks)

UBS analyst Jay Sole reiterates Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Neutral and maintains $73 price target.

News

Price Target

Reiteration

Analyst Ratings

UBS Reiterates Neutral on Nike, Maintains $73 Price Target

In the current market session, Domino's Pizza Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) share price is at $431.24, after a 0.06% increase. Moreover, over the past month, the stock fell by 9.49%, but in the past year, increased by 4.55%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1735222516_0.png" alt="Past Year Chart" />

<h3>Domino's Pizza P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Domino's Pizza has a lower P/E than the aggregate P/E of 81.76 of the Hotels, Restaurants &amp; Leisure industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1735222516_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Domino's Pizza

WIIM

OPTN

OptiNose shares are trading lower after the company announced a 1-for-15 reverse stock split.

<a target="_blank" href="https://www.benzinga.com/topic/big-banks?page=5" rel="noreferrer noopener">Major U.S. banks</a>, including JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), and Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), filed a lawsuit against the Federal Reserve on Tuesday, challenging the transparency of its annual stress test procedures.
Leading banking and business organizations, including the Bank Policy Institute (BPI), American Bankers Association (ABA), U.S. Chamber of Commerce, Ohio Bankers League, and Ohio Chamber of Commerce, joined the <a target="_blank" href="https://bpi.com/banks-and-business-groups-file-legal-challenge-against-federal-reserve-over-flawed-stress-testing-framework/" rel="noreferrer noopener">lawsuit </a>against the Federal Reserve. These tests, which assess banks&#8217; resilience during economic crises, are a cornerstone of financial risk management. However, the plaintiffs argue that the current system violates federal law by excluding required public input.
The litigation addresses long-standing concerns about the opacity of the Federal Reserve&#8217;s stress testing procedures, which the plaintiffs claim lead to excessive and volatile capital requirements. These charges, they say, hinder banks&#8217; ability to lend, support households and businesses, and contribute to economic growth. While acknowledging the importance of stress testing, the groups emphasize the need for reforms to create a fairer and more predictable regulatory environment.
Greg Baer, CEO of the BPI, stated that the current regime results in inaccurate and excessive capital charges, which reduce lending and stifle economic growth.
Rob Nichols, CEO of the ABA, criticized the stress tests for shielding critical supervisory models from public scrutiny.
Michael Adelman, CEO of the Ohio Bankers League, stressed that the lawsuit is about enforcing compliance with federal laws.
Tom Quaadman of the U.S. Chamber of Commerce highlighted the detrimental effects of the current system on small businesses, which rely on bank lending for growth.
The lawsuit follows the Fed&#8217;s <a href="https://www.federalreserve.gov/newsevents/pressreleases/bcreg20241223a.htm">recent </a>announcement to overhaul its stress test regime and seek public input on proposed changes in early 2025, the Wall Street Journal <a href="https://www.wsj.com/finance/regulation/banks-sue-federal-reserve-over-lack-of-transparency-in-stress-testing-0db6a002" target="_blank" rel="noreferrer noopener">reports</a>.
The lawsuit highlights the economic implications of unexpected capital burdens, stating they could impose &#8220;billions of dollars&#8221; in costs and negatively impact the broader economy.
The banks also noted that a statute of limitations on stress-test rule changes will expire in February, prompting their decision to file the suit now.
The latest test assessed how banks would manage a 40% decline in commercial real estate prices and a 36% drop in house prices.
The Federal Reserve evaluates these results to determine the total capital banks need to absorb potential losses, the Financial Times <a target="_blank" href="https://www.ft.com/content/56def327-dbf7-42f1-8aba-218259ebd4a1" rel="noreferrer noopener">reports</a>.
Since the 2008 financial crisis, banks have faced increased regulatory scrutiny, including stringent capital requirements.
Executives like Jamie Dimon of JPMorgan Chase and Brian Moynihan of Bank of America have criticized these rules for driving financial activities into less transparent markets.
The Federal Reserve&#8217;s Vice Chair for Supervision, Michael Barr, had proposed raising capital requirements for large banks but delayed those plans following industry opposition.
Six leading <a target="_blank" href="https://www.benzinga.com/government/24/06/39506407/6-biggest-us-banks-ramp-up-buybacks-undeterred-by-stress-tests" rel="noreferrer noopener">U.S. banks, including</a> JPMorgan Chase, Bank of America, Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), and Citigroup repurchased over $14 billion in shares in the first quarter.
In June, Bank of America analyst Ebrahim H. Poonawala criticized the Federal Reserve&#8217;s <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39531404/bank-of-america-analyst-highlights-fed-stress-test-opacity-varying-bank-impacts-gol" rel="noreferrer noopener">stress test process</a>, highlighting its &#8220;inherent opacity.&#8221; These evaluations, which assess banks&#8217; resilience under severe economic scenarios, revealed varying impacts on capital requirements. Poonawala noted that while banks demonstrated adequate buffers, the tests showed higher-than-expected losses.
In June, JPMorgan analyst Vivek Juneja analyzed the Federal Reserve&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39536951/bank-stress-tests-much-bigger-surprise-than-expected-will-delay-future-investment-p" target="_blank" rel="noreferrer noopener">annual stress test results</a>, highlighting larger-than-expected increases in stress capital buffers for major banks. He noted that the elevated capital requirements could delay or reduce long-term capital return strategies for these institutions.
Image via Shutterstock.

Legal

Media

Banks And Business Groups Challenge Fed's Stress Test Rules

As of Dec. 26, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">CorVel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVL#NASDAQ">CRVL</a>)</h3>
<ul>
<li>On Dec. 24, CorVel announced the effectiveness of three-for-one forward stock split. The company's stock surged around 38% over the past six months and has a <a href="https://www.benzinga.com/quote/CRVL">52-week high of $125.52</a>.</li>
<li>RSI Value: 84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CRVL Price Action: Shares of CorVel closed at $115.82 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">SES AI Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>)</h3>
<ul>
<li>On Oct. 31, SES AI posted third-quarter GAAP loss of 9 cents per share. &#8220;SES AI achieved several milestones in the third quarter, including building revenue pipeline from UAM and drones including with one of the world&#8217;s largest wireless communication providers, SoftBank. We also passed the GB38031-2020 global EV industry safety tests for its 100Ah Li-Metal cells, a major step towards C-samples and start-of-production for EV,&#8221; stated Dr. Qichao Hu, Founder and CEO. &#8220;Our ‘All-in on AI strategy&#8217; continues to power our success with our first revenue using our AI-accelerated battery material discovery expected in the fourth quarter of 2024 this year.&#8221; The company's stock gained around 82% over the past five days and <a href="https://www.benzinga.com/quote/SES">has a 52-week high</a> of $1.92.</li>
<li>RSI Value: 79</li>
<li>SES Price Action: Shares of SES closed at $0.71 on Tuesday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>

Short Ideas

Pre-Market Outlook

CRVL

Top 2 Health Care Stocks You May Want To Dump This Quarter

HGTV home renovation stars Jonathan and Drew Scott – best known as <a href="https://www.benzinga.com/real-estate/24/10/41601236/property-brothers-say-in-20-years-no-young-person-will-be-able-to-afford-a-home">the Property Brothers –</a> are fearful that Trump&#8217;s proposed tariffs could send construction costs soaring.
The brothers' native Canada, along with Mexico, has been in the President-elect&#8217;s tariff crosshairs, threatening that if both countries don&#8217;t stop the flow of migrants and drugs into the U.S., they will be hit economically through trade tariffs.
&#8220;Jonathan and I love the idea of domestic-made products,&#8221; real estate agent Drew Scott, one-half of the 6ft 5&#8243; identical twins, told<a href="https://www.bloomberg.com/news/features/2024-12-17/property-brothers-turned-reality-tv-home-renovation-craze-into-a-business-empire"> </a>Bloomberg. &#8220;There is a balance we need to strike,&#8221; Jonathan, the contractor of the two, added. &#8220;Blanket tariffs are not good for any economy,&#8221; he said. If those tariffs include essential building products such as steel and lumber, the results could be devastating for homeowners looking to renovate and the construction industry, causing newly built homes to increase prices sharply.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>
<h2 class="wp-block-heading">A $2.8 Billion Home Goods Empire and $200 Million Net Worth</h2>
The Scott Brothers have a lot at stake. They have a $2.8 billion home goods brand empire but, as TV hosts, they also have the added benefit of not simply relying on selling products to pay the bills. &#8220;We&#8217;ve made money in every kind of market possible,&#8221; Drew said. &#8220;Upmarket, down markets, buyer&#8217;s seller&#8217;s markets, it doesn&#8217;t matter.&#8221;
The brothers feel that extensive renovation projects and house flips will likely take a back seat in 2025 if interest rates do not come down. A trade war will only exacerbate things. The Scotts have plenty of outlets to invest their $200 million (according to Celebrity Net Worth) net worth if house flips falter.
See Also: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
<h2 class="wp-block-heading">Endorsement Magnets And Multiple Real Estate Reality TV Shows</h2>
They have created a fixer-upper reality TV empire, with dozens of HGTV shows, books and even a cruise under their umbrella. In addition, the Scotts have, according to Variety,<a href="https://variety.com/2022/tv/news/property-brothers-interview-billion-dollar-lifestyle-empire-1235439674/"> </a>multiple endorsements, appearing in ads for <a href="https://www.benzinga.com/news/24/12/42489378/whats-going-on-with-jpmorgan-chase-shares">Chase Bank</a>, LendingTree, ADT security, Dish Network and American Family Insurance, to name a few. The LA-based production company, Scott Brothers Entertainment, is home to their many TV shows. At the same time, their retail and e-commerce home-furnishing product lines are ubiquitous in multiple retail outlets such as Living Spaces, Macy's, <a href="https://www.benzinga.com/insights/options/24/12/42619016/home-depots-options-frenzy-what-you-need-to-know">Home Depot</a>, Lowe&#8217;s, Wayfair and Amazon. They also have a &#8220;Property Brothers Home Design&#8221; mobile app that debuted in 2019 with publisher Storm8. Everything is housed under their multibillion-dollar business, Scott Brothers Global.
<h2 class="wp-block-heading">A Venture Capital Fund</h2>
In addition, the brothers have created The Healthy Home Innovation Fund, a VC fund for home-related businesses and innovations.
&#8220;We said, &#8216;Well, why don&#8217;t we create a fund where we&#8217;re actually putting our money where our mouth is, find these young talents, get their ideas through our machine and to the next level?'&#8221; Jonathan told<a href="https://www.inc.com/chloe-aiello/the-property-brothers-built-a-multibillion-dollar-empire-now-theyre-helping-other-entrepreneurs.html"> I</a>nc.com. &#8220;And that&#8217;s the goal.&#8221;
Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
The brothers founded the Healthy Home Innovation Fund with GroundBreak Ventures and partner Sanders Lee in 2024. It is raising $50 million to $80 million to deploy to startups developing the latest technology for sustainable home improvement.
&#8220;Whether it&#8217;s decarbonizing your house, heat pumps, air quality in your home, how you transact, buy, sell, renovate or design – anything that touches home fits our pillars,&#8221; Drew added, explaining that he and Jonathan are &#8220;leveraging our brand and our facial awareness to help scale up some of these startups to really make them known, so we can bring the price points down to make it feasible for families.&#8221;
Tariffs or not, the Property Brothers' home renovation empire seems unlikely to crumble anytime soon.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

The Property Brothers Fear Trump's Tariffs Could Send Construction Costs Soaring

Meiwu Technology shares are trading lower. The company regained Nasdaq compliance.

NNDM

Nano Dimension shares are trading higher after the company announced a CEO transition.

SNAL

Snail shares are trading higher after Snail Games USA announced the launch of 'ARK: Ultimate Mobile Edition worldwide' on App Store and Google Play Store.

Snail Games Expands ARK Franchise With Launch Of ARK: Ultimate Mobile Edition And Updates To ARK: Extinction Ascended And Bob's Tall Tales: Wasteland War; Hits 1M Mobile Downloads In 24 Hours And 62% DAU Surge On Steam During Launch Weekend

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.
Shares of MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) fell sharply in today's pre-market trading following the company's announcement to issue more shares to finance additional Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) acquisitions. This move aligns with MicroStrategy's ongoing strategy to <a href="https://www.benzinga.com/quote/MSTR">bolster its Bitcoin reserves</a>.
MicroStrategy shares fell 3.5% to $345.65 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) shares dipped 10.1% to $10.01 in pre-market trading.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) declined 10% to $10.21 in pre-market trading.</li>
<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) fell 8.6% to $5.80 in pre-market trading.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) fell 8.6% to $11.21 in pre-market trading.</li>
<li>SunCoke Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXC#NYSE">SXC</a>) dipped 8.2% to $9.90 in pre-market trading.</li>
<li>Gray Television, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTN#NYSE">GTN</a>) fell 5.9% to $2.8505 in pre-market trading.</li>
<li>Portland General Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) slipped 2.5% to $42.69 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>

Movers

CGEM

DCTH

DSGN

NPCE

MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

The most oversold stocks in the utilities sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">National Grid plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGG#NYSE">NGG</a>)</h3>
<ul>
<li>On Nov. 20, National Grid named Steve Smith as Chief Strategy and Regulation Officer. &#8220;It&#8217;s a privilege to be appointed to this role at the most exciting time for the energy sector in decades,&#8221; said Steve Smith &#8220;The strategy and regulation teams already deliver outstanding work to ensure National Grid is set up for success and that we continue to put our customers first. I am very much looking forward to continuing to build on this, as I take up the role on a permanent basis.&#8221; The company's stock fell around 6% over the past month and has a <a href="https://www.benzinga.com/quote/NGG">52-week low of $55.13</a>.</li>
<li>RSI Value: 24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>NGG Price Action: Shares of National Grid fell 0.3% to close at $58.86 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122624&amp;t=be2bearmibe3na1">latest NGG news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="913" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084059/image-204.png" alt="" class="wp-image-707637" style="width:520px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084059/image-204.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084059/image-204-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084059/image-204-768x708.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<h3 class="wp-block-heading">American Electric Power Company Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Dec. 12, JP Morgan analyst Jeremy Tonet downgraded American Electric Power from Overweight to Neutral and lowered the price target from $109 to $102. The company's stock fell around 7% over the past month and <a href="https://www.benzinga.com/quote/AEP">has a 52-week low</a> of $75.22.</li>
<li>RSI Value: 29</li>
<li>AEP Price Action: Shares of American Electric Power fell 0.5% to close at $92.37 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122624&amp;t=be2bearmibe3na1">AEP stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="921" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084230/image-205.png" alt="" class="wp-image-707638" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084230/image-205.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084230/image-205-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084230/image-205-768x706.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
NextEra Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>)
<ul>
<li>On Dec. 12, Scotiabank analyst Andrew Weisel maintained NextEra Energy with a Sector Outperform and raised the price target from $92 to $96. The company's stock fell around 6% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/NEE">low of $53.95</a>.</li>
<li>RSI Value: 27</li>
<li>NEE Price Action: Shares of NextEra Energy gained 0.6% to close at $72.91 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122624&amp;t=be2bearmibe3na1">breakout in NEE shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="872" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084658/image-206.png" alt="" class="wp-image-707645" style="width:674px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084658/image-206.png 872w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084658/image-206-300x288.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26084658/image-206-768x737.png 768w" sizes="(max-width: 872px) 100vw, 872px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>

Long Ideas

Top 3 Utilities Stocks You'll Regret Missing In December

LAES

SEALSQ Launches SEALQUANTUM.com Lab To Advance Quantum-Safe Encryption And Post-Quantum Research, Strengthening Cybersecurity Solutions Against Emerging Quantum Threats

Management

Nano Dimension Appoints Julien Lederman As Interim CEO Following Termination Of Yoav Stern; Board Initiates Search For Permanent CEO

COEP

Coeptis Therapeutics Holdings shares are trading higher after the company announced it acquired NexGenAI Affiliated Network platform and the official launch of Coeptis Technologies.

SPRC

SciSparc shares are trading higher after the company announced it received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group.

Biotech

General

CASI

CASI Pharmaceuticals Announces FDA Clinical Hold On CID-103 For Kidney Transplant AMR; IND Application For Phase 1-2 Study In Chronic Immune Thrombocytopenia Remains Open With Accrual Expected To Begin Q1 2025; FDA To Provide Written Response Before Deadline

EVER

EverQuote shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy.

NTIP

Network-1 Initiates Patent Litigation Against Citadel Securities And Jump Trading For Patents-in-Suit, Which Are Part Of The HFT Patent Portfolio Acquire By HFT Solutions In 2022

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
There are thousands of U.S.-listed stocks categorized as <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>, or stocks trading for $5 per share or less but only a few can be considered strong buy penny stocks.



&ldquo;Penny stock territory&rdquo; contains a lot of busted growth stories, <a href="https://www.investopedia.com/terms/f/fallenangel.asp">fallen angels</a> and <a href="https://www.investopedia.com/terms/v/valuetrap.asp">value traps</a>, yet dive deep enough into the space, and you&rsquo;ll find plenty of asymmetric opportunities. In other words, stocks where upside potential vastly exceeds downside risk.



There are both growth and value plays within this category. The common denominator is that each of these stocks has one or several potential catalysts that could dramatically increase its respective underlying value.



While not all of them will live up to this potential, and in fact quite a few will miss the mark entirely, in the aggregate owning a basket of such stocks has the potential to produce stunning returns. With this in mind, let&rsquo;s take a look at seven strong buy penny stocks and why risk-hungry investors should consider buying them today.



<h2>Broadwind (BWEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/06/wind_turbine_1600-300x169.jpg" alt="A wind turbine appears in silhouette against a bright orange and blue sky."><div>Source: Khanthachai C / Shutterstock.com</div></div>Broadwind (NASDAQ:<a href="https://investorplace.com/stock-quotes/bwen-stock-quote/">BWEN</a>) is a manufacturer of industrial equipment used in clean energy infrastructure like wind turbines. Outside of the &ldquo;green wave stocks&rdquo; boom of 2021, and the smaller boom in such stocks around the time the Inflation Reduction Act was passed by Congress last year, BWEN has delivered a mixed performance.



However, lately BWEN stock has again been on a tear for reasons more company-specific in nature. That is, investors have jumped back into BWEN due to positive surprises with equipment maker&rsquo;s fiscal performance. Last quarter, the company beat on revenue and <a href="https://seekingalpha.com/news/4105683-broadwind-gaap-eps-of-0_07-beats-0_14-revenue-of-37_62m-beats-2_53m?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A4">unexpectedly reported positive GAAP earnings</a>. Broadwind also reported a <a href="https://investors.bwen.com/investor-news/investor-news-details/2024/Broadwind-Announces-First-Quarter-2024-Results/default.aspx">43.5%</a> sequential increase in orders.



BWEN bolted from just over $2 per share to nearly $4 per share since this well-received earnings release but the potential for additional upside remains. Forecasts call for Broadwind&rsquo;s earnings to increase sixfold next year, to <a href="https://www.wsj.com/market-data/quotes/BWEN">36 cents per share</a>. Such an improvement may prove sufficient to send the stock to even higher prices.



<h2>Elite Pharmaceuticals (ELTP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600-300x169.png" alt="pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory"><div>Source: Dmitry Kalinovsky / Shutterstock.com</div></div>In the past, I&rsquo;ve named Elite Pharmaceuticals (OTCMKTS:<a href="https://investorplace.com/stock-quotes/eltp-stock-quote/">ELTP</a>) as being one of the strong buy penny stocks. As discussed previously, shares in this over-the-counter (OTC) listed pharma firm delivered <a href="https://investorplace.com/2023/10/q4-stock-predictions-7-penny-stocks-ready-to-roar-into-2024/">an incredible performance during 2023</a>. During that time frame, ELTP went from 3 cents to 14 cents per share.



ELTP stock has continued to gain this year, albeit at a far slower pace compared to the preceding year. However, don&rsquo;t assume that the rate of price appreciation will continue to slow down to a trickle. Why? The company justed received Food and Drug Administration (FDA) <a href="https://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=134477&amp;BzID=2258&amp;g=939&amp;Nav=0&amp;LangID=1&amp;s=0">approval for a generic methotrexate drug product</a>. Methotrexate is an anti-rheumatic drug with a total annual addressable market estimated at $64.3 million.



That may sound like chump change for big pharma, yet for micro-cap ELTP it could really be a game-changer in terms of its operating performance in the years ahead. Last year, Elite&rsquo;s revenue totaled just $47.3 million. The stock currently trades at an inexpensive 10.8 times trailing 12 month (TTM) earnings. Alongside the prospect of rising in line with increased earnings, there may be potential for shares to be re-rated to a higher valuation.



<h2>E2 Open Parent Holdings (ETWO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/06/supply-chain-forklift-workers-1600-300x169.jpg" alt="silhouettes of a forklift and driver as well as two workers by a semi truck backdropped by a sunset sky. represents the supply chain"><div>Source: shutterstock.com/By yuttana Contributor Studio</div></div>E2 Open Parent Holdings (NYSE:<a href="https://investorplace.com/stock-quotes/etwo-stock-quote/">ETWO</a>) has more than doubled since October, but the incredible run in this supply chain management software purveyor may not be over. <a href="https://www.bloomberg.com/news/articles/2023-10-16/elliott-said-to-mull-buyout-of-supply-chain-software-firm-e2open">Shareholder activism and buyout rumors</a> have been a major factor behind ETWO&rsquo;s strong performance during this time frame.



In March the company announced it was beginning a <a href="https://seekingalpha.com/news/4077204-e2open-soars-after-announcing-start-of-strategic-review?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A5">&ldquo;strategic review,&rdquo;</a> which may include a sale of the company. ETWO stock has traded sideways since, but any news regarding a buyout could lead to another rally. That&rsquo;s not all. Even if takeover rumors ultimately fall apart, further improvement in E2 Open&rsquo;s operating performance may do the trick.



As InvestorPlace Earnings reported on Apr. 29, E2 Open <a href="https://investorplace.com/earning-results/2024/04/etwo-stock-earnings-e2open-parent-holdings-for-q4-of-2024/">beat on revenue and earnings</a> during the company&rsquo;s fiscal fourth quarter ending Feb. 29. Given that this $4.50 per share penny stock previously traded in the low-teens, even a partial recovery would represent big upside.



<h2>Lesaka Technologies (LSAK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/smartphone-mobile-financial-fintech-1600-300x169.jpg" alt="Illustration of phone with dollar sign and other graphics symbolizing fintech displayed on and around it, with a blue background. Fintech Stock Bargains. fintech stocks to buy"><div>Source: shutterstock.com/ZinetroN</div></div>I&rsquo;ve writen multiple times Lesaka Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/lsak-stock-quote/">LSAK</a>) is a <a href="https://investorplace.com/2024/05/7-fintech-stocks-to-buy-now-may-2024/">one of the best fintech stocks</a>. It is also <a href="https://investorplace.com/2024/05/investing-in-the-future-3-promising-penny-stocks-to-watch/">one of the strong buy penny stocks</a>. This South Africa-based fintech firm provides payment technology services in its home market and adjacent markets in Southern Africa. So far this year, the announcement of strategic acquisitions has bolstered confidence in the company&rsquo;s turnaround.



By acquiring competitors, Lesaka is positioning itself as the leading fintech services provider for South Africa&rsquo;s informal economy. The mergers will also likely produce significant cost savings, enabling the company to reach consistent profitability. While not certain, South Africa&rsquo;s recent general election may explain why LSAK stock has lost momentum after surging from $3.50 to nearly $5 per share.



Uncertainty exists over the African National Congress (ANC) needing to form a coalition government. It failed to win a majority and it was unknown whether the ANC would form one with centrist, pro-business parties or with parties less favorable to business and foreign investment. However, the latest developments suggest the planned Government of National Unity will <a href="https://www.reuters.com/world/africa/south-africa-is-forming-unity-government-what-happens-next-2024-06-12/">consist of the former</a> rather than the latter.



<h2>Moberg Pharma (MBGPF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/syringe-needle-biopharma-1600-1-300x169.jpg" alt="A syringe with a safety cap and a surgical mask laid out on a blank background"><div>Source: shutterstock.com/Michele Ursi</div></div>Moberg Pharma (OTCMKTS:<a href="https://investorplace.com/stock-quotes/mbgpf-stock-quote/">MBGPF</a>) is a Sweden-based pharmaceutical company focused primarily on the development of a nail fungus treatment. Since publication of a <a href="https://leftfieldinvesting.substack.com/p/moberg-pharma">bullish write-up</a> by Left Field Investing last November, this obscure company in a decidedly unglamorous business has <a href="https://twitter.com/search?q=Moberg%20Pharma&amp;src=typed_query&amp;f=live">garnered increased attention</a> among members of X&rsquo;s (formerly Twitter) &ldquo;Fintwit&rdquo; community.



Here&rsquo;s the bull case in a nutshell for Moberg. After <a href="https://www.mobergpharma.com/node/3560">success</a><a href="https://investorplace.com/stock-quotes/-stock-quote/"></a><a href="https://www.mobergpharma.com/node/3560">fully launching its treatment</a> Terclara in its home market, Moberg is now focused on commercializing it globally. The company thus far has inked commercial partnerships in five jurisdictions, including the European Union and Canada. Given the size of the total addressable market for this treatment and its Swedish market share, Moberg&rsquo;s target of up to <a href="https://www.mobergpharma.com/sites/default/files/moberg_pharma_q1_2024_240507_0.pdf">$500 million</a> in global product sales may be more than reasonable.



Not bad for a company with a market cap of just under $75 million. You can buy Moberg stateside in the OTC market where it trades as MBGPF stock. However, if you have access, a more liquid option may be to buy it via Moberg&rsquo;s main stock market listing, on the NASDAQ OMX Stockholm Nordic Exchange.



<h2>New Gold (NGD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/12/gold-300x169.jpg" alt="A pile of shining gold bars. Gold stocks"><div>Source: Shutterstock</div></div>New Gold (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ngd-stock-quote/">NGD</a>) is a Canada-based gold mining company. The company&rsquo;s main asset is its interest in the Rainy River mine, located in Northwestern Ontario. As you likely know, gold prices, while pulling back lately, have been rising in recent months.



NGD stock has spiked in price alongside this surge. Trading for just over $1 per share in February, New Gold is now at prices nearing $2 per share. Even if it seems that the gold rally is losing momentum, that may not necessarily be the case for NGD. At least, that&rsquo;s the takeaway from <a href="https://seekingalpha.com/news/4112012-new-gold-resumed-at-outperform-at-bmo-after-increasing-new-afton-stake?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A1">the recent reiteration of an &ldquo;Outperform&rdquo; rating</a> on the stock by BMO&rsquo;s Brian Quast.



On May 31, the sell-sider published a bullish research note on NGD. He cited significant increases in free cash flow ahead primarily due to New Gold increasing its interest in its New Afton copper and gold mine located in British Columbia. Trading for a reasonable 13.2 times forward earnings, the opportunity for increased cash flow could lead to further price appreciation for shares. In the event gold prices keep rising, this could be icing on the cake in terms of upside potential.



<h2>Pitney Bowes (PBI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/pbi-stock-1-300x169.jpg" alt="The office logo for Pitney Bowes on a glass building."><div>Source: JHVEPhoto / Shutterstock.com</div></div>Admittedly, Pitney Bowes (NYSE:<a href="https://investorplace.com/stock-quotes/pbi-stock-quote/">PBI</a>) is technically a penny stock right now. With a share price of $5.13 per share, PBI is just above what I like to call the &ldquo;penny stock ceiling.&rdquo; Even so, buying in now could still result in the sort of significant upside investors seek when investing in low-priced penny stocks.



As I&rsquo;ve discussed numerous times in coverage of PBI stock, an activist-led turnaround could result in <a href="https://investorplace.com/2024/04/dividend-diamonds-in-the-rough-7-undervalued-income-stocks/">the significant unlocking of shareholder value</a>. Obviously, with the stock up by 42.1% over the past year, this has already started to happen. Still, far greater upside may lie ahead. From the start activist investor Hestia Capital has estimated Pitney Bowes could eventually be worth between $11.34 and $16.33 per share.



Although Hestia and PBI still have plenty of work to do, recent developments signal they remain on track. As noted in a press release issued last month, PBI appointed a new interim CEO and announced plans to reduce annual operating expenses by as much as <a href="https://www.investorrelations.pitneybowes.com/news-releases/news-release-details/pitney-bowes-announces-leadership-transition-and-new-initiatives">$100 million</a>. It is also finalizing a strategic review that may result in a sale of one of Pitney Bowes&rsquo; subsidiaries.



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions,&nbsp;InvestorPlace does not publish commentary about companies that have a market cap of&nbsp;less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because&nbsp;these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market&nbsp;manipulators. If we ever do publish commentary on a low-volume stock that may be&nbsp;affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this&nbsp;fact and warn readers of the risks.



Read More:&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Thomas Niel held LSAK. He did not hold (either directly or indirectly) any positions in the other securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Thomas Niel, contributor for InvestorPlace.com, has been writing single-stock analysis for web-based publications since 2016.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/7-strong-buy-penny-stocks-to-buy-now-june-2024/">7 Strong Buy Penny Stocks to Buy Now: June 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Strong Buy Penny Stocks to Buy Now: June 2024

Consider Buying Moberg Pharma Ahead Of Drug Launch

BAYRY

BAYZF

BWEN

ELTP

ETWO

LSAK

MBGPF

Small Cap

Press Releases

Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU

Moberg Pharma

Comments

Moberg Pharma

News

Latest news for Moberg Pharma (OTC:MBGPF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga